SBI Capital Markets Limited (Manager to the Offer) has submitted to the Exchange a copy of Public Announcement for the attention of the Public Shareholders of Bliss GVS Pharma Limited under Regulation 3(1) and Regulation 4 read with Regulation 13(1), Regulation 14 and Regulation 15(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 equity shares (26% of Expanded Voting Share Capital) of Bliss GVS Pharma Limited at ₹299 per share. This mandatory open offer is triggered by a Share Purchase Agreement dated 23 May 2026, where the Acquirer agreed to purchase 4,58,03,024 shares (43.30% stake) from existing promoters and non-promoter shareholders for approximately ₹1,370 crore. The open offer consideration totals up to ₹829 crore assuming full acceptance. The Acquirer will become the new promoter holding up to 69.51% post-transaction, while existing promoters will exit or be reclassified to public category. Payment is entirely in cash. The open offer is not conditional on minimum acceptance.
Shareholders of Bliss GVS Pharma will receive ₹299 per share (cash) if they tender. The stock may trade near the offer price with a potential premium or discount depending on market sentiment about the acquisition and future business plans of Anupam Rasayan India.